Telix Pharmaceuticals has entered an agreement to acquire Canadian diagnostic imaging isotopes company ARTMS for $82 million.
Under the agreement, Telix will take on ARTMS’ cyclotron-based isotope production platform, manufacturing plant, and stockpile of ultrapure rare metals such as zinc-68, which is irradiated to produce gallium-68. The companies have been collaborating since 2020 to develop higher curie-scale production of Illuccix, a PET radiotracer injection kit used for prostate cancer imaging.
ARTMS is based in Burnaby, British Columbia, and is a privately held spin-off company of TRIUMF, Canada's particle accelerator center.
![A 53-year-old patient (patient number four) with a recurrent pituitary adenoma with extension of a cystic component of disease to the medial temporal lobe apparent on MRI (contoured in blue), and extension of disease to the left sphenoid bone and orbital apex apparent on [68Ga]Ga-DOTA-TATE (contoured in yellow).](https://img.auntminnie.com/mindful/smg/workspaces/default/uploads/2026/04/pituitary-tumor.QGsEnyB4bU.jpg?auto=format%2Ccompress&dpr=2&fit=crop&h=167&q=70&w=250)
